article thumbnail

NHC Submits Comments on CMS’ Proposed Rule on Marketplace Integrity and Affordability

Putting Patients First Blog

While we recognize CMS intent to strengthen program integrity and reduce fraud, we are deeply concerned that several provisions in this rule will create obstacles to coverage, increase out-of-pocket costs, and disproportionately impact vulnerable populations.

article thumbnail

AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

Express Pharma

On the global stage, AI and Machine Learning (ML) drove drug discovery and process optimisation, especially as large-scale pharma companies adopted AI for precision medicine. Building sophisticated laboratories, recruiting scientific talent, and collaborating with global research institutions are essential steps in this process.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharmacists Bridge the Gaps in Care Transitions

Pharmacy Times

Because documentation of medication lists is a key component of MTM, pharmacists are well positioned to incorporate this into transitions of care.” Because documentation of medication lists is a key component of MTM, pharmacists are well positioned to incorporate this into transitions of care.” Marsall M, Hornung T, Bäuerle A, Weigl M.

article thumbnail

Questions Patient Access Leaders Should Be Asking About AI (But Aren’t)

Pharmaceutical Commerce

We talked about the many closed-door conversations happening during vendor evaluations, RFP processes, or internal strategy meetings and identified some core questions access experts should be asking teams—internal or external. Look for a vendor with clear escalation processes when AI reaches its limits.

article thumbnail

How AI Brings Pharmacogenetics to the Frontline of Precision Medicine

Pharmacy Times

Personalized drug selection can lead to faster symptom control, fewer hospitalizations, and improved adherence—all of which contribute to better outcomes and a more streamlined care process. Real-World Evidence, Emerging Therapies, and Demonstrating Value Technological advances are accelerating this progress.

article thumbnail

Navigating Rilonacept Therapy: Dose Adjustments, Discontinuation, and Patient Support Strategies

Pharmacy Times

Rilonacept therapy management involves carefully evaluating patient disease stability, flare risks, and potential for discontinuation through a shared decision-making process. We on our own help to navigate patients through that process as well. That's an ongoing process, but that's one of the biggest questions.

article thumbnail

The GLP-1 Gold Rush: Why Compounded Alternatives Are a Risky Bet

Pharmaceutical Commerce

I'll explain why this "gold rush" is fraught with peril, from a risk management and insurance perspective. The elephant in the room: The critical absence of FDA approval The fundamental issue with compounded GLP-1s lies in their sidestepping of the rigorous FDA approval process.